Summit Therapeutics' stock surges as lung-cancer treatment vies with Merck's blockbuster
By Eleanor Laise
Experimental drug compares favorably against Keytruda in late-stage trial, Summit says
Shares of Summit Therapeutics Inc. (SMMT) jumped more than 270% Thursday after the company said its experimental cancer drug outperformed Merck & Co. Inc.'s blockbuster Keytruda in a late-stage clinical trial.
The trial compared the Summit drug, ivonescimab, with Keytruda in patients with non-small cell lung cancer whose tumors have positive expression of the protein PD-L1. Ivonescimab showed a statistically significant improvement in progression-free survival across patient subgroups, including those with high and low PD-L1 expression, Summit said in a release.
Miami-based Summit said it does not know of any previous phase 3 trials in non-small cell lung cancer that showed a statistically significant improvement over Keytruda in a head-to-head comparison. Summit believes the results are "the beginning of a paradigm change for treatment options for patients living with cancer," Robert Duggan, chairman and CEO, said in a statement.
Lung cancer is the leading cause of cancer deaths in the U.S., according to the Centers for Disease Control and Prevention. Roughly 80% to 85% of lung cancers are non-small cell lung cancer.
Summit said it plans to pursue development of ivonescimab in non-small cell lung cancer as well as other tumor types.
Keytruda, Merck's top-selling drug, generated over $25 billion in sales last year, up 19% from a year earlier.
Merck shares (MRK), which had gained ground earlier Thursday, dropped after the Summit announcement and finished the day down 1.1%.
Summit shares are up 318% in the year to date, while the S&P 500 SPX has climbed 9.8%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-30-24 1629ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying